Novo Nordisk A/s

High Point Pharmaceuticals, LLC

Other

Novo Nordisk Healthcare Ag

Novo Nordiskals

High Point Pharmacueticals, LLC

Henrik Sune Andersen

Knud Erik Andersen

Uffe Bang Olsen

Peter Madsen

Tine Krogh Jo Slashedrgensen

Rolf Hohlweg

Ursula Sonnewald

Hans Petersen

Frederik Christian Gro Slashednvald

Luke Milburn Judge

Ole Hvilsted Olsen

Yu Ge

Daniel Dale Holsworth

Frank Urban Axe

Gita Camilla Tejlgaard Kampen

Roy Teruyuki Uyeda

Todd Kevin Jones

Svend Treppendahl

Soren Ebdrup

Sven Branner

Farid Bakir

Jens Buchardt

Jesper F Lau

Thomas Kruse Hansen

Nils Langeland Johansen

Lars Fogh Iversen

Barry Zvi Shapira

Niels Peter Hundahl M&oslash;ller

Florenzio Zaragossa Dorwald

Silhankova Alexandra

Polivka Zdenek

Niels Peter Moller

Zdenek Polivka

John Paul Kilburn

William Charles Ripka

Carsten Behrens

Kristian Kjaergaard

Soeren Padkjaer

Susanne Nedergaard Grell

Birgitte Friedrichsen

Inge Thoger Christensen

Peder Lisby Noerby

Mette Dahl Andersen

Albrecht Gruhler

Jesper Kastrup

Katarina Haakansson

Lars Hornum

Dorrit Baunsgaard

Niels Peter Hundahl Møller

Wiliam Charles Ripka

Sindelar Karel

John Patrick Mogensen

Karel Sindelar

Alexandra Silhankova

Tine Krogh J&oslash;rgensen

Leif Noerskov-Lauritsen

Preben Broskov Nielsen

Annette Rosendal Larsen

Florenzio Zaragossa D&ouml;rwald

Polivka Zden&eacute;k

Silh&aacute;nkov&aacute; Alexandra

Sindel&aacute;r Karel

Claus Bekker Jeppesen

Patrick William Garibay

Sepehr Sarshar

Michael Ankersen

Bernd Peschke

Anker S Jorgensen

Lars Peter Klitmose

Michael James Newman

Frantisek Miksik

Bent Riber Petersen

Poul Borrevang

Søren Østergaard

John Thrane Hansen

Lutz Stefan Richter

Thomas Erik Mathiasen

Sonja Bak

Leif Norskov-Lauritsen

Anette Gundertofte

Kilburn Paul John

Enud Erik Andersen

Niels Peter Hundahl Moller

Josef Vagner

Jing Su

Adnan M M Mjalli

Niels Peter Hundahl Moeller

Carsten Enggaard Sitdsen

Niels Peter Mo Slashedller

Sidelar Karel

Tine Krough Jo Slashedrgensen

Bastienne Peelen

Tine Krogh Jo Slashedrgenen

Florenzio Zaragossa Do Slashedrwald

The present disclosure relates to treatment of inflammatory diseases. In particular, the present disclosure relates to antagonistic DR3 ligands useful for treating inflammatory diseases.

Antagonistic DR3 ligands

The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases.

The invention relates to growth hormone compounds with a protracted profile. The effect is obtained by linking an albumin binding residue via a hydrophilic spacer to growth hormone variants. Further described are methods of preparing and using such compounds. These growth hormone compounds are based on there altered profile considered particular useful in therapy.

Growth hormones with prolonged in-vivo efficacy

The invention relates to conjugated proteins, in particular but not exclusively, blood coagulation factors, to processes for preparing the conjugated proteins which contain the steps of reacting a protein or glycoprotein, such as factor VIIa or human growth hormone, with a water insoluble albumin binder in the presence of an optionally substituted cyclodextrin molecule, to pharmaceutical compositions comprising the protein conjugates and to the use of the protein conjugates in therapy, in particular but not exclusively, for the treatment of diseases alleviated by blood coagulation factors such as the prophylactic treatment of hemophilia.

Conjugated proteins with prolonged in vivo efficacy

The present invention relates to polypeptide compound optimized for subcutaneous administration, exemplified by growth hormone conjugates having a linker providing non-covalent binding to albumin.

The invention relates to growth hormone compounds with a protracted profile. The effect is obtained by linking an albumin binding residue via a hydrophilic spacer to growth hormone variants. Further described are methods of preparing and using such compounds. These growth hormone compounds are based on there althered profile considered particular useful in therapy.

The use of substituted amides for modulating the activity of 11&#x3b2;-hydroxysteroid dehydrogenase type 1 (11&#x3b2;HSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, of the general formula I. Their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11&#x3b2;HSDI and may be useful in the treatment of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable. 

11-beta-hydroxysteroid dehydrogenase type 1 active compounds

The use of substituted amides for modulating the activity of 11&#x3b2;-hydroxysteroid dehydro-genase type 1 (11&#x3b2;HSD1) and the use of these compounds as pharmaceutical composi-tions, are described. Also a novel class of substituted amides, their use in therapy, phar-maceutical compositions comprising the compounds, as well as their use in the manufac-ture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11&#x3b2;HSD1 and may be useful in the treatment of a range of medical disorders where a decreased intracellular concentration of active gluco-corticoid is desirable.

Pharmaceutical use of substituted amides

The use of substituted amides of structure (I) for modulating the activity of 11 &#x3b2;-hydroxysteroid dehydrogenase type 1 (11 &#x3b2;HSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11 &#x3b2;HSD1 and may be useful in the treatment, prevention and/or prophylaxis of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable. 

Indole- and benzimidazole amides as hydroxysteroid dehydrogenase inhibitors

A novel class of compounds of the general formula (I), their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds modulate the activity of 11 &#x3b2;-hydroxy-Steroid dehydrogenase type 1 (11&#x3b2;HSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, e.g. the metabolic syndrome. 

11&#x3b2;-hydroxysteroid dehydrogenase type 1 active spiro compounds

A novel class of compounds of the general formula (I), their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds modulate the activity of 11&#x3b2;-hydroxy-steroid dehydrogenase type 1 (11&#x3b2;HSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, e.g. the metabolic syndrome. 

11&#x3b2;-hydroxysteroid dehydrogenase type 1 active compounds

The use of substituted amides for modulating the activity of 11-hydroxysteroid dehydrogenase type 1 (11HSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11HSD1 and may be useful in the treatment, prevention and/or prophylaxis of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.

The use of fused 1,2,4-triazoles for modulating the activity of 11&#x3b2;-hydroxysteroid dehydrogenase type 1 (11&#x3b2;HSD1) and the use of these compounds as pharmaceutical compositions has been described. Also a novel class of fused 1,2,4-triazoles, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments has been described. The present compounds are modulators and more specifically inhibitors of the activity of 11&#x3b2;HSD1 and may be useful in the treatment, prevention and/or prophylaxis of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.

Pharmaceutical use of fused 1,2,4-triazoles

Growing community of inventors

Lyngby, Denmark

Henrik Sune Andersen